Cargando…
16例伴有睾丸侵犯的伯基特淋巴瘤患儿的临床特征及疗效分析
OBJECTIVE: To analyze the clinical features and outcomes of Burkitt lymphoma with testicular involvement and study the efficiency of high dose methotrexate (HD-MTX: 5–8g/m(2)) in those patients without radiation therapy. METHODS: Retrospective analysis was conducted in 16 Burkitt's lymphoma cas...
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
Editorial office of Chinese Journal of Hematology
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7342120/ https://www.ncbi.nlm.nih.gov/pubmed/27719719 http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2016.09.008 |
_version_ | 1783555372139675648 |
---|---|
collection | PubMed |
description | OBJECTIVE: To analyze the clinical features and outcomes of Burkitt lymphoma with testicular involvement and study the efficiency of high dose methotrexate (HD-MTX: 5–8g/m(2)) in those patients without radiation therapy. METHODS: Retrospective analysis was conducted in 16 Burkitt's lymphoma cases with testicular lymphoma involvement between Jan 2009 and Dec 2014. We followed the BCH-NHL-2009 protocol, modified from FAB LMB 89 combined with rituximab. All patients were enrolled in high-risk group (treated by Group C protocol). RESULTS: Of 137 Burkitt lymphoma, 16 (11.67%) had testicular involvement. All the patients were in stage Ⅳ, the median age was 6.65 years (ranges: 2.25 to 13.5 years). 8 cases had bone marrow involvement, 9 with central nervous system involvement, 5 with bi-testicular involvement, 1 with EB virus infection (EBV-IgM+). The median follow-up was 31.8 months (ranges: 0.5 to 79 months). During the study period, 2 cases died, 1 due to the disease relapse, the other one due to chemo-related dead. 1 had disease relapse 32 months after off treatment; the other 13 cases were all event free survival. 3-year OS was 87.5%, 3-year EFS was 72.9%. We also found the level of testosterone in ten adolescent were normal before and after chemotherapy. CONCLUSION: For the Burkitt lymphoma with testicular involvement, we abandon radiotherapy, and administer HD-MTX to lower the toxicity. The short-term survival is better, long-term survival still needs to be clarified. |
format | Online Article Text |
id | pubmed-7342120 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Editorial office of Chinese Journal of Hematology |
record_format | MEDLINE/PubMed |
spelling | pubmed-73421202020-07-16 16例伴有睾丸侵犯的伯基特淋巴瘤患儿的临床特征及疗效分析 Zhonghua Xue Ye Xue Za Zhi 论著 OBJECTIVE: To analyze the clinical features and outcomes of Burkitt lymphoma with testicular involvement and study the efficiency of high dose methotrexate (HD-MTX: 5–8g/m(2)) in those patients without radiation therapy. METHODS: Retrospective analysis was conducted in 16 Burkitt's lymphoma cases with testicular lymphoma involvement between Jan 2009 and Dec 2014. We followed the BCH-NHL-2009 protocol, modified from FAB LMB 89 combined with rituximab. All patients were enrolled in high-risk group (treated by Group C protocol). RESULTS: Of 137 Burkitt lymphoma, 16 (11.67%) had testicular involvement. All the patients were in stage Ⅳ, the median age was 6.65 years (ranges: 2.25 to 13.5 years). 8 cases had bone marrow involvement, 9 with central nervous system involvement, 5 with bi-testicular involvement, 1 with EB virus infection (EBV-IgM+). The median follow-up was 31.8 months (ranges: 0.5 to 79 months). During the study period, 2 cases died, 1 due to the disease relapse, the other one due to chemo-related dead. 1 had disease relapse 32 months after off treatment; the other 13 cases were all event free survival. 3-year OS was 87.5%, 3-year EFS was 72.9%. We also found the level of testosterone in ten adolescent were normal before and after chemotherapy. CONCLUSION: For the Burkitt lymphoma with testicular involvement, we abandon radiotherapy, and administer HD-MTX to lower the toxicity. The short-term survival is better, long-term survival still needs to be clarified. Editorial office of Chinese Journal of Hematology 2016-09 /pmc/articles/PMC7342120/ /pubmed/27719719 http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2016.09.008 Text en 2016年版权归中华医学会所有 http://creativecommons.org/licenses/by-nc-sa/3.0/ This work is licensed under a Creative Commons Attribution 3.0 License (CC-BY-NC). The Copyright own by Publisher. Without authorization, shall not reprint, except this publication article, shall not use this publication format design. Unless otherwise stated, all articles published in this journal do not represent the views of the Chinese Medical Association or the editorial board of this journal. |
spellingShingle | 论著 16例伴有睾丸侵犯的伯基特淋巴瘤患儿的临床特征及疗效分析 |
title | 16例伴有睾丸侵犯的伯基特淋巴瘤患儿的临床特征及疗效分析 |
title_full | 16例伴有睾丸侵犯的伯基特淋巴瘤患儿的临床特征及疗效分析 |
title_fullStr | 16例伴有睾丸侵犯的伯基特淋巴瘤患儿的临床特征及疗效分析 |
title_full_unstemmed | 16例伴有睾丸侵犯的伯基特淋巴瘤患儿的临床特征及疗效分析 |
title_short | 16例伴有睾丸侵犯的伯基特淋巴瘤患儿的临床特征及疗效分析 |
title_sort | 16例伴有睾丸侵犯的伯基特淋巴瘤患儿的临床特征及疗效分析 |
topic | 论著 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7342120/ https://www.ncbi.nlm.nih.gov/pubmed/27719719 http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2016.09.008 |
work_keys_str_mv | AT 16lìbànyǒugāowánqīnfàndebójītèlínbāliúhuànérdelínchuángtèzhēngjíliáoxiàofēnxī AT 16lìbànyǒugāowánqīnfàndebójītèlínbāliúhuànérdelínchuángtèzhēngjíliáoxiàofēnxī AT 16lìbànyǒugāowánqīnfàndebójītèlínbāliúhuànérdelínchuángtèzhēngjíliáoxiàofēnxī AT 16lìbànyǒugāowánqīnfàndebójītèlínbāliúhuànérdelínchuángtèzhēngjíliáoxiàofēnxī AT 16lìbànyǒugāowánqīnfàndebójītèlínbāliúhuànérdelínchuángtèzhēngjíliáoxiàofēnxī AT 16lìbànyǒugāowánqīnfàndebójītèlínbāliúhuànérdelínchuángtèzhēngjíliáoxiàofēnxī AT 16lìbànyǒugāowánqīnfàndebójītèlínbāliúhuànérdelínchuángtèzhēngjíliáoxiàofēnxī |